Current Report Filing (8-k)
May 27 2022 - 3:48PM
Edgar (US Regulatory)
0001314052
false
0001314052
2022-05-24
2022-05-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 24, 2022
ANAVEX
LIFE SCIENCES CORP.
(Exact
name of registrant as specified in its charter)
Nevada |
001-37606 |
98-0608404 |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
630
5th Avenue, 20th Floor, New York, NY USA 10111
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code 1-844-689-3939
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which
registered |
Common Stock, $0.001 par value |
|
AVXL |
|
The Nasdaq Stock Market LLC |
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
May 24, 2022, the Company held its Annual Meeting. A total of 53,355,147 shares of the Company’s Common Stock were present or represented
by proxy at the Annual Meeting, representing approximately sixty nine percent (69%) of the outstanding Common Stock as of March 28, 2022,
the record date for the Annual Meeting.
At
the Annual Meeting, three (3) proposals were submitted for a vote of the Company’s stockholders and the related results are as
follows:
Proposal
No. 1: The election of Christopher Missling, PhD, Claus van der Velden, PhD, Athanasios Skarpelos, Jiong Ma, PhD, Steffen Thomas,
PhD and Peter Donhauser, D.O. for terms until the next succeeding annual meeting of stockholders or until such directors’ successor
shall have been duly elected and qualified. The stockholders holding a majority of the Common Stock having voting power present in person
or represented by proxy elected the six (6) directors by the following votes:
Name | |
For | |
Withheld | |
Broker Non-Votes |
Christopher Missling, PhD | |
| 29,349,878 | | |
| 1,247,751 | | |
| 22,757,518 | |
Claus van der Velden, PhD | |
| 26,944,554 | | |
| 3,653,075 | | |
| 22,757,518 | |
Athanasios Skarpelos | |
| 27,597,270 | | |
| 3,000,359 | | |
| 22,757,518 | |
Jiong Ma, PhD | |
| 29,211,216 | | |
| 1,386,413 | | |
| 22,757,518 | |
Steffen Thomas, PhD | |
| 27,476,278 | | |
| 3,121,351 | | |
| 22,757,518 | |
Peter Donhauser, D.O. | |
| 27,155,102 | | |
| 3,442,527 | | |
| 22,757,518 | |
Proposal
No. 2: The stockholders holding a majority of the Common Stock having voting power present in person or represented by proxy ratified
Grant Thornton LLP as the Company’s independent registered accounting firm by the following votes:
For | |
Against | |
Abstain | |
Broker Non-Votes |
| 52,369,399 | | |
| 452,908 | | |
| 532,840 | | |
| — | |
Proposal
No. 3: The stockholders holding a majority of the Common Stock having voting power present in person or represented by proxy voted
to approve the 2022 Omnibus Incentive Plan by the following votes:
For | |
Against | |
Abstain | |
Broker Non-Votes |
| 19,233,911 | | |
| 10,676,227 | | |
| 687,491 | | |
| 22,757,518 | |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ANAVEX LIFE SCIENCES CORP. |
|
|
|
/s/ Christopher Missling |
|
Name: Christopher Missling, PhD |
|
Title: Chief Executive Officer |
|
|
Date: May 27, 2022 |
|
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2024 to May 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2023 to May 2024